The effect of insulin on circulating PCSK9 in postmenopausal obese women

Clinical Biochemistry

Volumn 47, Issue 12, 2014, Pages 1033-1039

  Awan, Zuhier ^a   Dubuc, Geneviève ^a   Faraj, May ^a,b   Dufour, Robert ^a   Seidah, Nabil G ^a   Davignon, Jean ^a   Rabasa Lhoret, Rémi ^a,b,c   Baass, Alexis ^a,d  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cholesterol; Euglycemic hyperinsulinemic clamp; Insulin; Insulin resistance; PCSK9

Indexed keywords

INSULIN; KEXIN; MESSENGER RNA; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SUBTILISIN; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CHRONIC DISEASE; COHORT ANALYSIS; DRUG EFFECT; FEMALE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; BLOOD; GENETICS; HYPERINSULINISM; METABOLISM; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION;

AGED; COHORT STUDIES; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; MIDDLE AGED; POSTMENOPAUSE; PROPROTEIN CONVERTASES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES;

EID: 84905752955     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.03.022     Document Type: Article

References (40)

1. Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100:928-933.
2. Maxwell K.N., Breslow J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004, 101:7100-7105.
3. Park S.W., Moon Y.A., Horton J.D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004, 279:50630-50638.
4. Benjannet S., Rhainds D., Essalmani R., Mayne J., Wickham L., Jin W., et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004, 279:48865-48875.
5. Zhang D.W., Lagace T.A., Garuti R., Zhao Z., McDonald M., Horton J.D., et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007, 282:18602-18612.
6. Kwon H.J., Lagace T.A., McNutt M.C., Horton J.D., Deisenhofer J. Molecular basis for LDL receptor recognition by PCSK9. Proc Natl Acad Sci U S A 2008, 105:1820-1825.
7. Zhang D.W., Garuti R., Tang W.J., Cohen J.C., Hobbs H.H. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A 2008, 105:13045-13050.
8. Nassoury N., Blasiole D.A., Tebon O.A., Benjannet S., Hamelin J., Poupon V., et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 2007, 8:718-732.
9. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
10. Leren T.P. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet 2004, 65:419-422.
11. Timms K.M., Wagner S., Samuels M.E., Forbey K., Goldfine H., Jammulapati S., et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004, 114:349-353.
12. Allard D., Amsellem S., Abifadel M., Trillard M., Devillers M., Luc G., et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005, 26:497.
13. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
14. Berge K.E., Ose L., Leren T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006, 26:1094-1100.
15. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
16. Denis M., Marcinkiewicz J., Zaid A., Gauthier D., Poirier S., Lazure C., et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 2012 Feb 21, 125:894-901.
17. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
18. Baass A., Dubuc G., Tremblay M., Delvin E.E., O'Loughlin J., Levy E., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
19. Cui Q., Ju X., Yang T., Zhang M., Tang W., Chen Q., et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis 2010, 213:632-636.
20. Browning J.D., Horton J.D. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010, 51:3359-3363.
21. Kappelle P.J., Lambert G., Dahlbäck B., Nielsen L.B., Dullaart R.P. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. Atherosclerosis 2011 Feb, 214(2):492-494.
22. Brouwers M.C., Troutt J.S., van Greevenbroek M.M., Ferreira I., Feskens E.J., van der Kallen C.J., et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. Atherosclerosis 2011, 217:263-267.
23. Costet P., Cariou B., Lambert G., Lalanne F., Lardeux B., Jarnoux A.L., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006, 281:6211-6218.
24. Niesen M., Bedi M., Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys 2008, 470:111-115.
25. Persson L., Galman C., Angelin B., Rudling M. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology 2009, 150:1140-1146.
26. St-Pierre D.H., Bastard J.P., Coderre L., Brochu M., Karelis A.D., Lavoie M.E., et al. Association of acylated ghrelin profiles with chronic inflammatory markers in overweight and obese postmenopausal women: a MONET study. Eur J Endocrinol 2007, 157:419-426.
27. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia Jul 1985, 28(7):412-419.
28. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.
29. Dubuc G., Tremblay M., Pare G., Jacques H., Hamelin J., Benjannet S., et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010, 51:140-149.
30. Lipari M.T., Li W., Moran P., Kong-Beltran M., Sai T., Lai J., et al. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem 2012 Dec 21, 287(52):43482-43491.
31. Kappelle P.J., Lambert G., Dullaart R.P. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients. Atherosclerosis 2011, 214:432-435.
32. Monzillo L.U., Hamdy O. Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev 2003, 61:397-412.
33. Hammana I., Coderre L., Potvin S., Costa M., Berthiaume Y., Lavoie A., et al. Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study. J Cyst Fibros 2009, 8:128-134.
34. Duvillard L., Florentin E., Lizard G., Petit J.M., Galland F., Monier S., et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 2003, 26:1540-1544.
35. Chakravarty K., Wu S.Y., Chiang C.M., Samols D., Hanson R.W. SREBP-1c and Sp1 interact to regulate transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in the liver. J Biol Chem 2004, 279:15385-15395.
36. Grefhorst A., McNutt M.C., Lagace T.A., Horton J.D. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J Lipid Res 2008, 49:1303-1311.
37. Cariou B., Langhi C., Le Bras M., Bortolotti M., Lê K.A., Theytaz F., et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab (Lond) Jan 8 2013, 10(1):4.
38. Awan Z., Seidah N.G., MacFadyen J.G., Benjannet S., Chasman D.I., Ridker P.M., et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 2012 Jan, 58(1):183-189.
39. Dubuc G., Chamberland A., Wassef H., Davignon J., Seidah N.G., Bernier L., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
40. Li H., Dong B., Park S.W., Lee H.S., Chen W., Liu J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem 2009, 284:28885-28895.